Switching from existing anti-VEGF agents to ranibizumab BS in age-related macular degeneratio
Not Applicable
Recruiting
- Conditions
- Age-Related Macular Degeneration
- Registration Number
- JPRN-UMIN000048394
- Lead Sponsor
- agoya university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with unstable drug administration intervals with TAE regimen using existing anti-VEGF drugs, patients with other concomitant ocular diseases such as active uveitis and proliferative diabetic retinopathy, patients who have undergone previous vitrectomy or treatment with unknown details at other hospitals, and patients for whom anterior chamber fluid sampling by anterior chamber puncture is deemed unsafe.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interval/frequency of anti-VEGF agents during the follow-up period
- Secondary Outcome Measures
Name Time Method